Skip to main content Help with accessibility Skip to main navigation

CLOZAPINE: reducing the risk of harm

CCG Approval Status:

Date Added: 29 - Aug - 2023
Body System:

Everyone involved in the support or care of people receiving clozapine is reminded of the importance of awareness and management of common side effects that may lead to life threatening conditions.

  • Constipation must be actively monitored and actively treated. Clozapine carries a serious risk of intestinal obstruction including faecal impaction and paralytic ileu.
  • Be cautious with signs or symptoms of a low white cell count. Clinical or haematological neutropenia or agranulocytosis can lead to an acute life threatening condition.
  • Monitor closely for tachycardia. Clozapine also carries a serious risk of myocarditis and cardiomyopathy particularly in the first two months of treatment.

NHS Cheshire and Merseyside APPROVED